Dr. Richard J.D. Hatley MChem, DPhil, MRSC, CChem

Formally a scientific leader at GlaxoSmithKline (GSK), Richard is a medicinal chemist with 20 years experience. He has wide drug discovery expertise across therapeutic areas with detailed knowledge of hit-to-lead and lead-optimisation phases to deliver candidate molecules. He is an outstanding team leader and his interpersonal skills have enabled many successful projects. He has devised and delivered the synthetic chemistry routes for many programmes, including several candidate drug molecules entering the clinic.

In the last five years he was lead chemist on alpha-v integrin drug discovery programmes, enabling the discovery of the next generation oral and inhaled integrin inhibitors. He has an international standing in the integrin field as lead author with high impact publications (Integrin drug discovery. Angew Chem Int Ed Engl. 2018, 57, 3298-3321 (Impact factor 12) ; Fibrosis Toolbox, Nat. Rev. Drug Disc. 2015, 14, 693-720 (Impact factor 57). He has organised several RSC medicinal chemistry conferences on Fibrosis in 2015 and 2017 and on Integrins in 2019. He is an honorary lecturer in medicinal chemistry at the University of East Anglia (UEA).

Dr. Simon J. F. Macdonald BSc, MSc, PhD

Simon has over 30 years experience at GSK in drug discovery across many therapeutic areas and routes of delivery with a track record for innovation and working cross-discipline and cross-institutions. He has significant expertise in delivering clinical candidates, managing collaborations and in organising and teaching undergraduate courses.

As a Director in Medicinal Chemistry in the Fibrosis Discovery Performance Unit at GSK, Simon led the drug discovery team that delivered multiple integrin clinical candidates. He was one of the most published medicinal chemists in GSK worldwide with over 100 publications including 34 patents (h-index of 30). With a long track record of collaboration, he was the GSK lead for the successful 2019 £12.8m EPSRC Prosperity Partnership grant with the Universities of Nottingham and Strathclyde.

His most recent publications describe integrin drug discovery including high impact factor reviews. He is also co-author on a series of highly cited papers about aromatic ring count developability in drug discovery. For the past nine years, Simon has been a visiting professor at the University of Nottingham where he co-led bespoke undergraduate teaching modules in live drug discovery programmes and was co-awarded the Lord Dearing Prize for teaching in 2017.